SEARCH BY NAME

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

AVANTOGEN LIMITED (ACU)

Former Name ASX

SHARE PRICES

(discontinued 17 July 2020)

Former (or subsequent) names

 FROMTO
PLUS CONNECT LIMITED09/05/2018
ACTIVISTIC LIMITED13/05/201509/05/2018
ACUVAX LIMITED05/12/200813/05/2015
AVANTOGEN LIMITED31/05/200505/12/2008
AUSTRALIAN CANCER TECHNOLOGY LIMITED04/05/200131/05/2005
EXODUS MINERALS LIMITED14/08/199704/05/2001
MINERALS MINING AND METALLURGY LIMITED14/08/1997

Shareholder links

 

REGISTRY:
Security Transfer Australia Pty Ltd, 770 Canning Highway Applecross WA 6153
Tel : +61 3 9628 2200
Fax : +61 8 9315 2233
RegistryWebsite RegistryEmail

Company details

Address: 44 Martin Place , SYDNEY , NSW, AUSTRALIA, 2000
Tel:  (02) 9252 6899 Fax: (02) 9252 6877

Date first listed: 25/08/1971
Company Secretary: Mr Phillip MacLeod
Sector: Pharmaceuticals & Biotechnology
Industry Group: XHJ
Activities: Drug development company focused on products including a potential therapy for pancreatic cancer, vaccine adjuvants and a cancer vaccine.

name changed to Acuvax Limited

05/12/2008

securities reinstated to quotation

03/10/2007

releases its 2007 annual report

27/09/2007

releases progress report - expects to hold an annual general meeting about 30 November 2007

19/09/2007

the company is going to apply to ASX for the re-quotation of its shares

06/09/2007

company releases its Preliminary Final Report

31/08/2007

company releases its Half Yearly Report and Accounts

07/08/2007

at the AGM on 11 June, all resolutions were passed on a show of hands

13/06/2007

the company issues another 274m shares and now has 548m on isuue

22/05/2007

releases supplementary prospectus & advises of completion of rights issue

16/05/2007

provides Notice of AGM for 4pm on 11 June at office of Lavan Legal , Level 20, 1 William St, Perth

11/05/2007

the company completes major transaction with SciClone Pharmaceuticals Inc

27/04/2007

company releases its Annual Report

24/04/2007

the company announces that it has entered into a strategic alliance with The Medingen Group, LLC of Canandaigua, New York to sublicense a line of nutraceutical products previously known as `revisys', which will subsequently be re-branded under the name `Encore'

15/03/2007

releases a Half Yearly Report

01/03/2007

releases its unaudited 2006 Financial Statements

28/02/2007

ASIC issues an interim stop order on the rights issue prospectus

28/02/2007

cash flow for the quarter ended 30 December 2006 reflects a deficit at operating level of $1,847k

30/01/2007

releases top 20 shareholders/Distribution Schedule

10/01/2007

the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders

20/12/2006

shareholders are reminded that the Chopin offer closes at 12 midnight tomorrow (Wednesday) evening - the offer is not fair as the total consideration is less than the market value of the assets to be acquired - but in consideration of other factors, the offers are reasonable

19/12/2006

Chopin grants shareholders an extension of time to approve loan facilities

19/12/2006

company provides quite a detailed update - the cash position is deteriorating and efforts are being made to re-finance the company - shareholders should read the update which can be sourced at www.asx.com.au

14/12/2006

directors attempt to report on what transpired at the AGM on November 30 is abysmal - one shareholder asked questions about the takeover and at the very least directors should have reported to all shareholders on the substance of the questions and answers

01/12/2006

directors advise of a deteriorating cash position and of attempts to seek further funding

30/11/2006

the meeting to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane is to proceed but it will no longer be an AGM as the company has not finalised the financial statements - it will be a special meeting allowing shareholders to put questions to the board

24/11/2006

company files its quarterly report

14/11/2006

advises in relation to the Chopin Opus bid, that the defeating conditions of the Bidder's Statement (s 3.7) have been waived

10/11/2006

AGM to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane

08/11/2006

ASIC has refused the company's application for an extension of time to hold its AGM and the company will now make arrangements to hold it as soon as practicable

03/11/2006

company secures a $200,000 loan facility for its immediate short term financing needs

31/10/2006

cash flow report for the quarter to 30 September 2006 reflects a deficit at operating level of $1851k for the quarter

30/10/2006

ASX queries the company regarding Listing Rule 10.1 and the company states that it applies to the loan agreement between Anvantogen Oncology and Chopin Opus (see note immediately below) and accordingly the company will seek shareholder approval "for grant of the security by way of promissory note and the issue of the warrants prior to the warrants being issued"

27/10/2006

the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders

19/10/2006

advises of minor amendments to the bidder's statement

17/10/2006

company reports it has sufficient cash to fund activities through to the end of November and is currently seeking additional funding of $200,000

17/10/2006

releases Bidder's Statement & Target's Statement re the Chopin Opus offer

05/10/2006

Avantogen Ocology Inc submits an investigational drug application to the FDA for a compound being investigated for treatment of pancreatic cancer

02/10/2006

company says it is doing everything possible to resolve the accounting issues underlying its suspension

27/09/2006

Dr William Ardrey appointed CEO and Company Secretary

25/09/2006

advises it has secured a $1.8 million Loan facility

19/09/2006

lodges bidders statement from Chopin Opus

19/09/2006

lodges initial response to bidders statement from Chopin Opus

19/09/2006

releases Preliminary Final Report

14/09/2006

shares suspended from quotation pending resolution of accounting issues

11/09/2006

name changed from Australian Cancer Technology Limited

31/05/2005

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Patrick ElliottChairman
    William ArdreyCEO29/08/2006
    Lauro ValdovinosNon Exec Director
    Yvonne FoongDirector13/12/2006
    David SandersDirector

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION

    Date of first appointment, title may have changed.